Literature DB >> 26890856

A novel dual lock method for down-regulation of genes, in which a target mRNA is captured at 2 independent positions by linked locked nucleic acid antisense oligonucleotides.

Ryohei Takata1,2,3, Gouki Makado1,3, Ayaka Kitamura1,2,3, Hajime Watanabe1,2, Tadashi Wada1.   

Abstract

Nuclear factor κB (NFκB), which is composed of the RelA and p50 subunits, binds to NFκB response elements (NREs) and stimulates the transcription of inflammation-related genes. Here, locked nucleic acid (LNA) antisense oligonucleotides (ASOs) complementary to the termini of the 3'- and 5'-untranslated regions (UTRs) of the RelA mRNA were generated; these molecules were named 3'-LNA and 5'-LNA, respectively. To evaluate their effects on NFκB activity, HeLa cells were co-transfected with the LNA ASOs and a luciferase reporter gene carrying an NRE. Transfection of the cells with 3'-LNA reduced NFκB activity by 30-40%, without affecting RelA mRNA accumulation. Concomitant transfection of HeLa cells with 5'-LNA and 3'-LNA resulted in a 70% reduction in NFκB activity. Furthermore, partial poly(A) tail shortening occurred in LNA ASO-transfected cells. We also employed triethylene glycol as a spacer to link 5'-LNA and 3'-LNA. Reporter gene assays showed that the spacer-linked LNA ASO reduced NFκB activity similarly to a combination of 5'-LNA and 3'-LNA. In addition, an in vitro translation assay revealed that spacer-linked LNA ASOs inhibited the translation of a target mRNA in a specific manner. In summary, this study describes a novel antisense method capturing the target mRNA at independent positions.

Entities:  

Keywords:  Antisense; LNA; dual lock; poly(A); untranslated region

Mesh:

Substances:

Year:  2016        PMID: 26890856      PMCID: PMC4829292          DOI: 10.1080/15476286.2015.1119364

Source DB:  PubMed          Journal:  RNA Biol        ISSN: 1547-6286            Impact factor:   4.652


  52 in total

1.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5' UTR as in the 3' UTR.

Authors:  J Robin Lytle; Therese A Yario; Joan A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-29       Impact factor: 11.205

2.  MicroRNAs direct rapid deadenylation of mRNA.

Authors:  Ligang Wu; Jihua Fan; Joel G Belasco
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-22       Impact factor: 11.205

3.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.

Authors:  A Fire; S Xu; M K Montgomery; S A Kostas; S E Driver; C C Mello
Journal:  Nature       Date:  1998-02-19       Impact factor: 49.962

4.  MicroRNAs mediate gene silencing via multiple different pathways in drosophila.

Authors:  Takashi Fukaya; Yukihide Tomari
Journal:  Mol Cell       Date:  2012-11-01       Impact factor: 17.970

Review 5.  Antisense oligonucleotides: promise and reality.

Authors:  I Lebedeva; C A Stein
Journal:  Annu Rev Pharmacol Toxicol       Date:  2001       Impact factor: 13.820

6.  Chemically Modified Antisense Oligonucleotides-Recent Improvements of RNA Binding and Ribonuclease H Recruitment.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  1999-12-03       Impact factor: 15.336

7.  alpha-L-ribo-configured locked nucleic acid (alpha-L-LNA): synthesis and properties.

Authors:  Mads D Sørensen; Lisbet Kvaernø; Torsten Bryld; Anders E Håkansson; Birgit Verbeure; Gilles Gaubert; Piet Herdewijn; Jesper Wengel
Journal:  J Am Chem Soc       Date:  2002-03-13       Impact factor: 15.419

8.  Design of antisense oligonucleotides stabilized by locked nucleic acids.

Authors:  Jens Kurreck; Eliza Wyszko; Clemens Gillen; Volker A Erdmann
Journal:  Nucleic Acids Res       Date:  2002-05-01       Impact factor: 16.971

Review 9.  Cytokine signaling modules in inflammatory responses.

Authors:  John J O'Shea; Peter J Murray
Journal:  Immunity       Date:  2008-04       Impact factor: 31.745

Review 10.  Interfering with disease: a progress report on siRNA-based therapeutics.

Authors:  Antonin de Fougerolles; Hans-Peter Vornlocher; John Maraganore; Judy Lieberman
Journal:  Nat Rev Drug Discov       Date:  2007-06       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.